New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
06:17 EDTARDXArdelyx 4.286M share IPO priced at $14.00
The deal was increased to 4.286M shares from 3.6M shares and priced between the $13.00-$15.00 range. Citigroup and Leerink acted as joint book running managers for the offering.
News For ARDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
15:07 EDTARDXArdelyx shares up 7.38% after tenapanor data, potential milestone payments
15:05 EDTARDXArdelyx scheduled for end Phase 2 meeting with FDA scheduled in June
Subscribe for More Information
14:56 EDTARDXArdelyx jumps 6%, halted for volatility after reporting tenapanor trial data
14:53 EDTARDXArdelyx presents positive results from trial evaluating tenapanor
Ardelyx presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. As previously reported, at the 50 mg dose of tenapanor, the study met its primary efficacy endpoint of an increase in the complete spontaneous bowel movement, CSBM, responder rate. Most secondary endpoints, including abdominal pain and other abdominal and IBS-C symptoms, demonstrated clinically meaningful improvements. Tenapanor was well-tolerated, and the safety results were consistent with those observed in previous tenapanor trials. The findings were presented today in an oral presentation entitled, "Efficacy and Safety of Tenapanor in Patients with Constipation Predominant Irritable Bowel Syndrome: A 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial" at the Digestive Disease Week, DDW, 2015 conference being held in Washington, D.C. from May 16-19.
May 12, 2015
16:20 EDTARDXArdelyx reports Q1 EPS (19c), consensus 1c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use